Más Información

PAN abre las puertas a Grecia Quiroz como candidata a gubernatura de Michoacán; Jorge Romero reconoce su determinación y valentía

¿Qué es y quiénes integran la Comisión Nacional de Elecciones de Morena?; Citlalli Hernández la dirige rumbo al 2027

Rosa Icela Rodríguez evita responder si busca gubernatura en SLP; temas electorales no son de esta tribuna, dice en la mañanera

Rafael Marín Mollinedo visita a Mario Villanueva; exgobernador de Quintana Roo se encuentra en arresto domiciliario

FGR solicita a EU deportación de Bertha Olga Gómez Fong, esposa de César Duarte; es señalada por peculado
Mexico’s Foreign Affairs Minister Marcelo Ebrard Casaubón announced that Mexico has reached agreements with three companies that are developing COVID-19 vaccines to perform late-stage clinical trials in our country.
During president Andrés Manuel López Obrador’s morning news conference, Minister Ebrard said they are two companies from China and one from the United States, with which – he said – our country is participating in four protocols for the development of the vaccine.
The company from the United States is Janssen Pharmaceutical while the ones from China are Cansino Biologics and Walvax Technology.
As part of the memorandum of understanding, the late stage of the clinical protocols for the vaccine will take place in Mexico, that is, there will be clinical trials in our country from September 2020 through January 2021.
Recommended:
Moreover, Ebrard Casaubón said Mexico is working with 15 companies so that our country has timely access to the vaccine against the new disease once it is developed.
The Foreign Affairs Minister said our country was the first one to make a proposal in that regard at the G20 meeting and to present a related initiative that was unanimously approved at the United Nations.

In the case of Mexican citizens that have been repatriated due to the coronavirus pandemic, Marcelo Ebrard said that so far, the government has helped 16,874 Mexicans abroad.
Recommended:
mp
Noticias según tus intereses
[Publicidad]
[Publicidad]









